-
New Ypsilon and Ypsilon hf
-
The Cupra Raval will be launched in 2026
-
New id.Polo comes electric
-
Iran defies US threats to insist on right to enrich uranium
-
Seifert powers New Zealand to their record T20 World Cup chase
-
Naib's fifty lifts Afghanistan to 182-6 against New Zealand
-
Paul Thomas Anderson wins top director prize for 'One Battle After Another'
-
De Beers sale drags in diamond doldrums
-
NFL embraces fashion as league seeks new audiences
-
What's at stake for Indian agriculture in Trump's trade deal?
-
Real Madrid can wait - Siraj's dream night after late T20 call-up
-
Castle's monster night fuels Spurs, Rockets rally to beat Thunder
-
Japan votes in snow-hit snap polls as Takaichi eyes strong mandate
-
Pakistan's capital picks concrete over trees, angering residents
-
Berlin's crumbling 'Russian houses' trapped in bureaucratic limbo
-
Neglected killer: kala-azar disease surges in Kenya
-
Super Bowl set for Patriots-Seahawks showdown as politics swirl
-
Sengun shines as Rockets rally to beat NBA champion Thunder
-
Matsuyama grabs PGA Phoenix Open lead with Hisatsune one back
-
Washington Post CEO out after sweeping job cuts
-
Haiti's transitional council hands power to PM
-
N. Korea to hold party congress in February, first since 2021
-
Thailand votes after three leaders in two years
-
Swiss joy as Von Allmen wins first gold of Winter Olympics
-
George backs England to 'kick on' after Six Nations rout of Wales
-
Malinin upstaged as Japan keep pressure on USA in skating team event
-
Vail's golden comets Vonn and Shiffrin inspire those who follow
-
Veteran French politician loses culture post over Epstein links
-
Japan's Kimura wins Olympic snowboard big air gold
-
Arteta backs confident Gyokeres to hit 'highest level'
-
Hojlund the hero as Napoli snatch late win at Genoa
-
England's Arundell 'frustrated' despite hat-trick in Wales romp
-
Lollobrigida skates to first Italian gold of Winter Olympics on her birthday
-
Arundell hat-trick inspires England thrashing of Wales in Six Nations opener
-
Chile's climate summit chief to lead plastic pollution treaty talks
-
Rosenior hails 'unstoppable' Palmer after treble tames Wolves
-
French ex-minister offers resignation from Paris cultural hub over Epstein links
-
New NBA dunk contest champ assured and shooting stars return
-
Shiffrin says will use lessons learnt from Beijing flop at 2026 Games
-
Takaichi tipped for big win as Japan votes
-
Lens return top of Ligue 1 with win over Rennes
-
Shiffrin learning from Beijing lessons ahead of Milan-Cortina bow
-
Demonstrators in Berlin call for fall of Iran's Islamic republic
-
'Free the mountains!": clashes at Milan protest over Winter Olympics
-
Townsend accepts pressure will mount on him after Italy defeat
-
BMW iX3 new style and design
-
Suryakumar's 84 leads India to opening win over USA in T20 World Cup
-
Lollobrigida skates to first Italian gold of Milan-Cortina Games
-
Barca beat Mallorca to extend Liga lead
-
Gyokeres lifts Arsenal nine clear as Man Utd pile pressure on Frank
US panel recommends Covid vaccines for youngest children
A panel of experts convened by the US Food and Drug Administration unanimously recommended Covid-19 vaccines Wednesday for children under five, the final age group awaiting immunization in most countries.
Formal authorizations should follow soon, with the first shots in arms expected early next week, just over a year-and-a-half after the first Covid vaccines were greenlighted for the elderly in December 2020.
"This recommendation does fill a significant unmet need for a really ignored younger population," said Michael Nelson, a professor of medicine at the University of Virginia, one of the 21 experts asked to vote for the milestone meeting.
Unlike regulators in other countries, FDA offers livestreams of its internal deliberations and its stamp of approval is considered the global gold standard.
Opening the discussion, senior FDA scientist Peter Marks said that despite studies showing the majority of children have now been infected with the coronavirus, the high rate of hospitalizations among infants, toddlers and young children during last winter's Omicron wave underscored an urgent need for vaccination.
"We are dealing with an issue where we have to be careful we don't become numb to the pediatric deaths because of the overwhelming number of older deaths," he said.
"Every life is important and vaccine-preventable deaths are something we would like to try to do something about."
The United States has recorded 480 Covid deaths in the 0-4 age group in the pandemic -- far higher than even a bad flu season, Marks said.
As of May 2022, there have been 45,000 hospitalizations in that group, nearly a quarter of which required intensive care.
Ahead of the meeting, the FDA posted its independent analyses of the pharmaceutical companies' vaccines, deeming both safe and effective.
Both vaccines are based on messenger RNA, which delivers genetic code for the coronavirus spike protein to human cells that then grow it on their surface, training the immune system to be ready. The technology is now considered the leading Covid vaccination platform.
Pfizer sought authorization for three doses at three micrograms given to children aged six months through four years, while Moderna asked for the FDA to authorize its vaccine as two doses of a higher 25 micrograms for ages six months through five years.
Both vaccines were tested in trials of thousands of children. They were found to cause similar levels of mild side effects as in older age groups and triggered similar levels of antibodies.
- Two doses, or three? -
Efficacy against infection was higher for Pfizer, with the company placing it at 80 percent, compared to Moderna's estimates of 51 percent for children aged six-months to two years old and 37 percent for those aged two to five years.
But the Pfizer figure is based on very few cases and is thus considered preliminary. It also takes three doses to achieve its protection, with the third shot given eight weeks after the second, which is given three weeks after the first.
Moderna's vaccine should provide strong protection against severe disease after two doses, given four weeks apart, and the company is studying adding a booster that would raise efficacy levels against mild disease.
However, Moderna's decision to go with a higher dose is associated with higher levels of fevers in reaction to the vaccine compared to Pfizer.
There are some 20 million US children aged four years and under.
Although obesity, neurological disorders and asthma are associated with increased risk of severe disease among young children, it's not easy to predict severe outcomes.
In fact, 64 percent of hospitalizations in those under five occurred in patients without comorbidities.
Children can also go on to contract multisystem inflammatory syndrome in children (MIS-C), a rare but serious post-viral condition. Some three to six percent can experience long Covid symptoms for more than 12 weeks.
The FDA is expected to soon act on the panel's recommendation, and the matter will go to the Centers for Disease Control and Prevention for a final say.
White House officials last week said the rollout of 10 million shots at pharmacies and doctors' offices could begin as soon as June 21.
J.Williams--AMWN